Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers
Aromatase inhibitors are used to treat oestrogen-receptor-positive breast cancer. Here, the authors use genomic approaches to analyse tumours before and after neo-adjuvant treatment and find that treatment alters the clonal landscape of the tumours.
Guardado en:
Autores principales: | Christopher A. Miller, Yevgeniy Gindin, Charles Lu, Obi L Griffith, Malachi Griffith, Dong Shen, Jeremy Hoog, Tiandao Li, David E. Larson, Mark Watson, Sherri R Davies, Kelly Hunt, Vera J. Suman, Jacqueline Snider, Thomas Walsh, Graham A. Colditz, Katherine DeSchryver, Richard K. Wilson, Elaine R. Mardis, Matthew J. Ellis |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a6ce0b4a6c5a4496be23087aef9be2f5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution.
por: Christopher A Miller, et al.
Publicado: (2014) -
Anti-estrogenic and anti-aromatase activities of citrus peels major compounds in breast cancer
por: Dina M. El-Kersh, et al.
Publicado: (2021) -
Effect Of Microgravity On Aromatase Expression In Sertoli Cells
por: Elisa Cirelli, et al.
Publicado: (2017) -
Interactions of aromatase and seladin-1: A neurosteroidogenic and gender perspective
por: Kelicen-Ugur Pelin, et al.
Publicado: (2019) -
Are another 5 years of adjuvant aromatase inhibitor therapy needed?
por: Mo QG, et al.
Publicado: (2016)